Please assess the completion status of the following clinical trial:

Trial Title: Low Level Laser Therapy to Reduce Pain After Breast Augmentation Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Suitability for breast augmentation surgery based on the need for correction of a congenital deformity or condition such as: Amastia, Hypomastia, Hypoplasia, Pectus Carinatum, Pectus Excavatum, OR a cosmetic breast enhancement indication, including: Augmentation to increase breast size, correction of ptotic (drooping) or pendulous (sagging) breasts, recontouring to obtain enhanced breast shape.~* Bilateral breast augmentation indication only.~* 18 to 55 years, inclusive.~* Female, only.~* Willingness, and ability, to refrain from consuming over-the-counter and/or prescription medications for the indication of the relief of pain and/or swelling, including any non-steroidal anit-inflammatory drugs (NSAIDs), from 48 hours immediately prior to the laser-assisted breast implant procedure through to one week post-procedure.~Exclusion Criteria:~* Breast augmentation procedures indicated for the purpose of breast reconstruction following mastectomy or an injury due to severe trauma.~* Presence of a specific connective tissue disorder.~* Inadequate tissue available to cover the implants.~* Consumption of any one or more of narcotics, opiates, and/or steroids.~* Inability to consume the following medications post-operatively due to allergy, intolerance, or any other reason:~  (i) Pain medication for the relief of post-operative pain of Lortab 10/500 or another drug within the combination narcotic analgesic drug category within which Lortab falls.~(ii) Antibiotic medication for reducing the risk of post-operative infection of Keflex 500 mg or Cipro 500 mg or another drug within the broad-spectrum antibiotic drug category within which Keflex and Cipro fall.~* Developmental disability or cognitive impairment that impacts a subject's ability to read and/or to understand the content of the informed consent form, and/or impacts a subject's ability to read and /or to understand and/or to complete the required case report form information for the clinical study.~* Significant psychological disorder(s) for which treatment has become necessary, including anxiety and depression; psychiatric hospitalization.~* Pregnancy or lactation.~* Prior surgery to the breast area, or to the area of the intended incision.~* Infection or wound in the intended areas of treatment.~* Involvement in litigation and/or receiving disability benefits related to the subject's breast(s).~* Participation in research over the preceding 90 days.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Placebo Laser (Type: SHAM_COMPARATOR): Placebo Laser is an inactive light
- Erchonia EML Laser (Type: ACTIVE_COMPARATOR): Erchonia EML Laser uses two 7mW red 635nm wavelength light emitting CSRH Class IIIb laser diodes. The energy delivered is 1.5 J/cm2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete